JP2021527090A5 - - Google Patents

Info

Publication number
JP2021527090A5
JP2021527090A5 JP2020569002A JP2020569002A JP2021527090A5 JP 2021527090 A5 JP2021527090 A5 JP 2021527090A5 JP 2020569002 A JP2020569002 A JP 2020569002A JP 2020569002 A JP2020569002 A JP 2020569002A JP 2021527090 A5 JP2021527090 A5 JP 2021527090A5
Authority
JP
Japan
Prior art keywords
dose
aminosterol
pharmaceutical composition
subject
sleep
Prior art date
Application number
JP2020569002A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019241503A5 (https=
JP2021527090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036946 external-priority patent/WO2019241503A1/en
Publication of JP2021527090A publication Critical patent/JP2021527090A/ja
Publication of JPWO2019241503A5 publication Critical patent/JPWO2019241503A5/ja
Publication of JP2021527090A5 publication Critical patent/JP2021527090A5/ja
Pending legal-status Critical Current

Links

JP2020569002A 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 Pending JP2021527090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
US62/684,496 2018-06-13
PCT/US2019/036946 WO2019241503A1 (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Publications (3)

Publication Number Publication Date
JP2021527090A JP2021527090A (ja) 2021-10-11
JPWO2019241503A5 JPWO2019241503A5 (https=) 2022-04-22
JP2021527090A5 true JP2021527090A5 (https=) 2022-04-22

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569002A Pending JP2021527090A (ja) 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物

Country Status (11)

Country Link
US (2) US20190381071A1 (https=)
EP (1) EP3806862A4 (https=)
JP (1) JP2021527090A (https=)
KR (1) KR20210009422A (https=)
CN (1) CN112566641A (https=)
AU (1) AU2019285065A1 (https=)
BR (1) BR112020025296A2 (https=)
CA (1) CA3103463A1 (https=)
MX (1) MX2020013614A (https=)
SG (1) SG11202012343TA (https=)
WO (1) WO2019241503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) * 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
WO2022244929A1 (ko) * 2021-05-21 2022-11-24 애니머스큐어 주식회사 이노토디올을 포함하는 근육 질환의 예방 또는 치료용 조성물
WO2025054408A1 (en) * 2023-09-07 2025-03-13 NeuroTherapia, Inc. Methods of treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Similar Documents

Publication Publication Date Title
JP2021527090A5 (https=)
ES3021189T3 (en) Treatment of angelman syndrome with gaboxadol
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
EP4483956B1 (en) TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3)
JP2011521954A (ja) 神経及び精神障害の治療法
JP2022540253A (ja) Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
JP2019524834A (ja) ビグアナイド系による発達障害の治療方法
WO2021025973A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
WO2021025974A1 (en) Human squalamine derivatives, related compositions comprising the same, and methods of using the same
AU2021206771A1 (en) Cognitive disorder prevention and therapy
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
JPWO2019241503A5 (https=)
US20210260078A1 (en) Low dosage intranasal aminosterol dosage forms and methods of using the same
US20250345433A1 (en) Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It
Nicoletti et al. Treatment with dimethyl fumarate enhances cholinergic transmission in multiple sclerosis
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
US20230190724A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
De Pasqua Myotonic syndromes: analysis of factors with pathogenetic and prognostic significance
US20230381168A1 (en) Adjunctive therapy for depression
US20200038416A1 (en) Methods of treating cardiac conduction defects using aminosterol compositions
WO2023007320A1 (en) Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN121419776A (zh) 治疗多发性硬化症的伊博格碱
HK40037184A (en) Use of riluzole prodrugs to treat ataxias